Shares in specialty pharmaceutical company Antares Pharma (Nasdaq: ATRS) were up by nearly half at lunchtime on Wednesday with the news that the firm is to be acquired by Halozyme Therapeutics (Nasdaq: HALO).
According to Halozyme, the transaction, which values Antares at approximately $960 million, will be immediately accretive to the company’s 2022 revenue and non-GAAP earnings and will to accelerate top- and bottom-line growth through 2027, with multiple growth drivers beyond 2027.
"The addition of Antares, particularly with its best-in-class auto injector platform and specialty commercial business, augments Halozyme's strategy"Halozyme's flagship innovation is its ENHANZE technology, a solution which can reduce hours-long treatments to a matter of minutes and has touched more than 600,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. The company licenses this tech to leading pharma and biotech companies including Roche (ROG: SIX), Pfizer (NYSE: PFE), AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze